Dose response modelling of secretory cell loss in salivary glands using PSMA PET

Xerostomia remains a common side effect of radiotherapy (RT) for patients with head and neck (H&N) cancer despite advancements in treatment planning and delivery. Secretory salivary gland cells express the prostate-specific membrane antigen (PSMA), and show significant uptake on PET scans using ⁶⁸Ga/¹⁸F-PSMA-ligands. We aimed to objectively quantify the dose-response of salivary glands to RT using PSMA PET.

28H&N cancer patients received RT with 70 Gy in 35 fractions over 7 weeks. PSMA PET/CT was acquired at baseline (BL), during treatment (DT) and at 1-&6-months post-treatment (PT_1M/PT_6M). Dose, BL- PT_1M- and PT_6M-SUV were extracted for every voxel inside each parotid (PG) and submandibular (SMG) gland. The PT_1M/6M data was analysed using a generalised linear mixed effects model.Patient-reported xerostomia and DT-PSMA loss was also analysed.

Dose had a relative effect on BL SUV. For a population average gland (BL-SUV of 10), every 1 Gy increment, decreased the PT_1M/PT_6M-SUV by 1.6 %/1.6 % for PGs and by 0.9 %/1.8 % for SMGs. TD₅₀ of the population curves was 26.5/31.3 Gy for PGs, and 22.9/27.8 Gy for SMGs at PT_1M /PT_6M. PSMA loss correlated well with patient-reported xerostomia at DT/PT_1M (Spearman's ρ = -0.64, -0.50).

A strong relationship was demonstrated between radiation dose and loss of secretory cells in salivary glands derived using PSMA PET/CT. The population curve could potentially be used as a dose planning objective, by maximising the predicted post-treatment SUV. BL scans could be used to further tailor this to individual patients.